Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Positron Emission Tomography01:29

Positron Emission Tomography

Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body being...
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Subtype-Specific Metabolic Patterns in Staging Breast Cancer: Insights from Conventional and Parametric PET Radiomics.

Cancers·2026
Same authorSame journal

Shaping the role of FDG PET in bladder cancer: current evidence and ongoing clinical trial.

The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...·2026
Same author

FAPI PET-guided tumor volume delineation for radiotherapy planning: A comprehensive review across solid tumors.

Seminars in nuclear medicine·2026
Same author

From center to edge: Prognostic implications of spatial metabolic heterogeneity, normalized hotspot-to-centroid and perimeter distance, on PET imaging. A systematic review and meta-analysis.

European journal of nuclear medicine and molecular imaging·2026
Same author

Predictive role of ultrasonography in the early diagnosis of Hirschsprung's disease in neonates and infants: an observational diagnostic study.

Emergency radiology·2026
Same author

Fibrous Dysplasia With 99m Tc-FAPI Uptake in a Patient Under Long-term Antiresorptive Therapy.

Clinical nuclear medicine·2026

Related Experiment Video

Updated: May 16, 2026

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

Response assessment in [177Lu]PSMA: where do we stand?

Priscilla Guglielmo1,2, Atena Aghaee3, Sajjad Sadeghpour3

  • 1Nuclear Medicine Unit, Humanitas Gavazzeni, Bergamo, Italy - priscilla.guglielmo@yahoo.it.

The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of
|May 14, 2026
PubMed
Summary

Nuclear medicine imaging, including [177Lu]Lu-PSMA SPECT/CT and PSMA PET/CT, effectively monitors treatment response in prostate cancer. Volumetric data from these scans can predict survival outcomes, guiding future prospective trials.

More Related Videos

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Related Experiment Videos

Last Updated: May 16, 2026

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Area of Science:

  • Nuclear Medicine
  • Radiopharmaceuticals
  • Oncology

Background:

  • Lutetium-177 (177Lu) PSMA-targeted radionuclide therapy (RLT) is a key treatment for advanced prostate cancer.
  • Assessing treatment response to 177Lu-PSMA RLT is crucial for patient management and therapeutic optimization.
  • Current nuclear medicine imaging modalities offer insights into treatment efficacy but require critical analysis.

Purpose of the Study:

  • To review and critically analyze nuclear medicine procedures for assessing treatment response to 177Lu-PSMA RLT.
  • To highlight the strengths and limitations of current imaging techniques.
  • To discuss future developments in response assessment for 177Lu-PSMA therapy.

Main Methods:

  • Comprehensive literature search of PubMed and Scopus databases until August 2025.
  • Search strings combined terms for prostate cancer, Lutetium-177 PSMA, and treatment response assessment.
  • Included English-language studies and screened reference lists for additional relevant publications.

Main Results:

  • 23 studies with 1419 patients were analyzed; most were retrospective.
  • [68Ga]Ga-PSMA-11 PET/CT was the most common imaging modality for response assessment.
  • SPECT/CT and PET/CT volumetric data demonstrated prognostic utility for survival outcomes at various time points.

Conclusions:

  • [177Lu]Lu-PSMA SPECT/CT and PSMA PET/CT are valuable for monitoring response to PSMA-RLT.
  • Combination with PSA levels can aid response monitoring.
  • High heterogeneity necessitates prospective trials to standardize response assessment.